2025-05-23-Jefferies-太阳制药工业（SUNP）_太阳制药2025财年第四季度符合预期_降低短期预期_14页_858kb

报告摘要

Sun Pharmaceutical Industries - Equity Research Summary

Executive Summary

Sun Pharmaceutical Industries reported Q4 FY25 results in line with estimates but experienced a profit-after-tax (PAT) miss due to one-time factors, including litigation settlements and impairments. The company revised its FY26 growth guidance to mid to high single-digit, below earlier expectations, primarily due to competition from Stelara biosimilars and global uncertainties. The analyst maintains a Buy rating with an INR2,000 price target, based on 33x FY27 EPS, while adjusting for risks in specialty drug growth and macroeconomic headwinds.

Q4 FY25 Performance

Revenue: INR128.2bn (+8% YoY/-5% QoQ), in line with Jefferies estimates. India growth was robust at 14% YoY, while US specialty sales declined 2% QoQ due to insurance contract negotiations.
PAT: Missed by 2% due to exceptional losses (INR3.1bn from opiate litigation, INR3.7bn DTA write-off), impacting performance despite core operations stability.
Segment Breakdown: US revenue down 2% QoQ (specialty drag), India up 14% YoY, Emerging Markets stable, RoW affected by currency.

FY26 Guidance

Growth: Revised to mid to high single-digit (original estimate was low double-digit), driven by competitive pressures from Stelara biosimilars and Steladyne patent loss.
Key Factors: Moderate growth expected due to global uncertainty (MFN, tariffs, currency); catalysts include Ilumya psoriatic arthritis data and Leqselvi launch.

Key Catalysts

Product Milestones: Leqselvi expected to launch by 2QFY26; several FY26 data readouts for Ilumya and other specialty drugs.
Acquisitions: Acquisition of Checkpoint Therapeutics for USD416m to bolster PD-L1 treatment portfolio.
Growth Drivers: Specialty portfolio traction, particularly in emerging markets, supported by new launches and R&D investments.

Financial Projections

Revenue: CAGR of 9% for FY25-27E (FY26E: INR563,667bn), reflecting stable growth in India and specialty segments.
EBITDA: Expected to grow at 8-11% CAGR, margins stabilizing at 28-29% due to cost control.
EPS: To reach INR60.5 by FY27E, with higher tax rates (6-8%) reducing profitability.
Valuation: Target P/E of 33x FY27 EPS; revenue growth expected to moderate in FY26 due to competition.

Analyst Rating

Current Rating: Buy (maintained), with target price INR2,000 (down from previous).
Rationale: Long-term growth potential in global specialty and India markets, offset by near-term risks; FY26/27 EPS revised down 3%/6% due to lower growth and higher taxes.

Risks

Product-Related: Quality issues (historical Ranbaxy import alerts) could disrupt supply.
Macro-Related: Global uncertainties (MFN, tariffs, currency), slower Ilumya growth, and competition from biosimilars.
Financial: Rising raw material costs, stock-based compensation, tax rate volatility.